肺腺癌（LUAD）是肺癌最常见的病理亚型。铁死亡（ferroptosis）是一种依赖铁离子并且非凋亡性的细胞死亡方式，与多种癌症的发生和进展高度相关。溶质载体家族7成员11（SLC7A11）维持半胱氨酸和谷氨酸的反向转运活性，调节铁死亡。我们从TCGA和GEO数据库中收集了批量RNA测序和单细胞RNA测序数据。然后，我们提取了SLC7A11的表达水平，对正常组织和LUAD组织进行差异表达分析。接着，我们进行了生存分析、单变量和多变量Cox回归分析，以探索SLC7A11在LUAD中的预测价值。基因集富集分析用于探索SLC7A11在LUAD中的潜在分子机制。最后，我们分析了SLC7A11与免疫状态和免疫治疗疗效的关系。LUAD组织中SLC7A11的表达水平显著增加。生存分析、单变量和多变量Cox回归分析表明，SLC7A11是LUAD患者预后的负面因素。基因集富集分析揭示低表达组富集了几个与免疫相关的通路。较低的SLC7A11水平对免疫治疗有更好的疗效，并且具有较低的免疫逃逸和功能失调的概率。SLC7A11是与预后相关的生物标志物，并与LUAD患者的免疫状态和免疫治疗疗效密切相关，可以作为评估预后和免疫治疗疗效的有效生物标志物。版权所有 © 2023 作者。由 Wolters Kluwer Health, Inc. 发布。

Lung adenocarcinoma (LUAD) is the most common pathological subtype of lung cancer. Ferroptosis is an iron-dependent, non-apoptotic cell death mode, highly correlated with the tumorigenesis and progression of multiple cancers. Solute carrier family 7 member 11 (SLC7A11) maintains the anti-porter activity of cysteine and glutamate to regulate ferroptosis. We collected bulk RNA-seq and scRNA-seq from The Cancer Genome Altas and Gene Expression Omnibus databases. Then, we extracted the expression level of SLC7A11 to perform the differential expression analysis between normal tissues and LUAD tissues. Then, we applied survival, univariate, and multivariate Cox regression analyses to investigate the predictive value of SLC7A11 in LUAD. Gene set enrichment analysis was used to explore the underlying molecular mechanisms of SLC7A11 in LUAD. Finally, we analyzed the relationship of SLC7A11 to the immune status and the curative effect of immunotherapy. The expression level of SLC7A11 in LUAD tissues was markedly increased. The survival analysis, univariate and multivariate Cox regression analysis showed that SLC7A11 was a negative factor for the prognosis of LUAD patients. Gene set enrichment analysis revealed that several immune-related pathways were enriched in the low-level group. The lower SLC7A11 level has a better therapeutic effect of immunotherapy and less probability of immune escape and dysfunction. SLC7A11 was a prognostic-related biomarker and closely correlated with the immune status and therapeutic effect of immunotherapy in LUAD, which could be an effective biomarker for evaluating the prognosis and the therapeutic efficacy of immunotherapy.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.